Rheumatology Department, Charité CBF, Berlin, Germany.
Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S159-63.
Disease modifying antirheumatic drugs (DMARDs) are widely used and well accepted for the treatment of patients with rheumatoid arthritis (RA). Many studies have been performed with monotherapy and combinations of DMARDs showing their efficacy and safety. In ankylosing spondylitis (AS) DMARDs, sulfasalazine especially, are recommended only for the peripheral involvement and not for the axial symptoms. For this disease there is a lack of clinical trials and most of the trials did not show efficacy on the axial symptoms of the disease. In this paper, the differences and similarities of DMARDs in the treatment of RA and AS patients will be discussed.
疾病修饰抗风湿药物（DMARDs）广泛用于治疗类风湿关节炎（RA）患者，并被广泛接受。许多研究已经对 DMARDs 的单药治疗和联合治疗进行了研究，显示了其疗效和安全性。在强直性脊柱炎（AS）中，DMARDs，特别是柳氮磺胺吡啶，仅推荐用于外周受累，而不用于轴症状。对于这种疾病，缺乏临床试验，并且大多数试验都没有显示出对疾病轴症状的疗效。本文将讨论 DMARDs 在治疗 RA 和 AS 患者中的差异和相似之处。
